Ac-PHSCN-NH2

N/A

Report date: 2022/11/25 17:25:29
NME

Base Information

Drug NameAc-PHSCN-NH2
Drug Alias NameATN-161Ac-PHSCN-NH2
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionIntegrin alpha-5/beta-1 antagonistsIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-5/beta-1Integrin alpha-V/beta-3
Therapy Area/IndicationsCNS Embryonal TumorCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAttenuon Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Attenuon Llc
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksDrugBank